Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Clinical trial NCT02864992 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02864992
Sponsor: EMD Serono Research & Development Institute, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification Lung Adenocarcinoma Stage IIIB/IV

Start date: 2016-09-13
Primary completion: 2022-05-16
Enrollment: 337

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.